M
Metagenomi Inc
NASDAQ:MGX
Metagenomi Inc
NASDAQ:MGX
Price:
1.6
USD
8.11%
Market Closed
Market Cap:
$60m
Relative Value
The Relative Value of one MGX stock under the Base Case scenario is 2.01 USD. Compared to the current market price of 1.6 USD, Metagenomi Inc is Undervalued by 21%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MGX
Relative Value
Base Case
2.01
USD
Undervaluation 21%
M
Multiples Across Competitors
MGX Competitors Multiples
Metagenomi Inc Competitors
Metagenomi Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
M
|
Metagenomi Inc
NASDAQ:MGX
|
60.1m USD | 1.9 | -0.7 | 1.4 | 1.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.1B USD | 6.6 | 96.1 | 15.8 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.2B USD | 5.5 | 26.3 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182B USD | 6.2 | 21.4 | 13.3 | 16.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.1B USD | 9.8 | 29.6 | 22.3 | 23.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD | 5.8 | 18.3 | 13.8 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.4B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
38.4B EUR | 11.1 | 35.8 | 38.9 | 39.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
